Tiffany, Kors to Re...
Health Care: Drugs
Idenix Pharmaceuticals Inc. (IDIX: NASDAQ)
$4.31 0.12 | 2.86%
05/24/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 4.31 |
| 52 Week High | 11.30 |
| 52 Week Low | 3.21 |
| Avg. Daily Vol. (Mil) | 0.89 |
| Beta (3 year) | 0.35 |
| Share Related Items | |
| Mkt Cap (Mil) | 577.36 |
| Shares Out (Mil) | 133.96 |
| Float (Mil) | 75.58 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 9.40 |
| Current Ratio | 9.70 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 16.56 |
| Price/Book | 3.06 |
| Price/Cash Flow | -8.10 |
| Per Share Data | |
| Earnings | -0.61 |
| Sales | 0.26 |
| Book Value | 1.41 |
| Cash Flow | -0.53 |
| Business Summary | |
|---|---|
| Idenix Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and Europe. | |
| General Information | |
| 60 Hamphire Street
Cambridge, MA 02139 |
|
| www.idenix.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 107 | |
| CEO: Ronald C. Renaud,Jr | |
| Short Interest | |
| Current Month (Mil) | 14.09 |
| Previous Month (Mil) | 14.27 |
| Short Interest Ratio (Days) | 17.10 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -32.90 |
| Return on Investments | -39.00 |
| Profitability | |
| Gross Margin | 94.80 |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with IDIX
- Portfolio NameUser Type
- ProSeth Klarman - Baupost Group
- ContributorBreakout Stocks Of The Week...
- ContributorBreakout Stocks Of The Week...
- ContributorMost-Active Stocks for the ...
- ContributorStocks Under-$10 Moving Hig...
- Userdonnieny7 Portfolio 1 Specu...
- ContributorStocks Rising On Unusual Vo...
- Usernew
- UserLong Term Stock Picks
- ContributorStocks Under-$10 Setting Up...
Latest IDIX Headlines from TheStreet
- Idenix Announces Data Presentation At The 48th Annual Meeting Of The European Association For The Study Of The Liver (EASL) 04.08.13 | 04:04 pm
- Idenix Loses First Phase Of Patent Dispute With Gilead Sciences 03.25.13 | 07:03 am
- Stock Futures Rise as Cyprus Deal Is Clinched 03.25.13 | 06:03 am
- Idenix Pharmaceuticals Announces Decision By The United States Patent And Trademark Office Patent Trial And Appeal Board In The First Phase Of The Interference 03.22.13 | 04:03 pm
- Idenix Pharmaceuticals To Present At Two Upcoming Investor Conferences 02.26.13 | 04:02 pm
- Idenix Pharmaceuticals Reports Fourth Quarter And Year Ended 2012 Financial Results 02.25.13 | 04:02 pm
- Fisking Ray Dirks on Medgenics and Shaming Seeking Alpha 02.11.13 | 09:02 pm
- Biotech Stock Mailbag: Dynavax, ImmunoCellular, Celldex and Medgenics 02.08.13 | 06:02 am
- Idenix Pharmaceuticals To Present At Two Upcoming Investor Conferences 02.05.13 | 04:02 pm
- Idenix Pharmaceuticals Provides Update On IDX184 And IDX19368 Development Programs 02.04.13 | 04:02 pm
Press Releases for IDIX
- Idenix Pharmaceuticals Announces Declaration Of A Patent Interference By The USPTO - PR Newswire 03.06.12 | 08:03 am
- Idenix Pharmaceuticals Elects Thomas Hodgson As Chairman Of The Board And Appoints Michael Wyzga To Its Board Of Directors - PR Newswire 03.01.12 | 04:03 pm
- Idenix Pharmaceuticals To Present At Three Upcoming Investor Conferences - PR Newswire 02.29.12 | 04:02 pm
- Idenix Pharmaceuticals To Present At The Citi Global Healthcare Conference - PR Newswire 02.21.12 | 04:02 pm
- Idenix To Host Conference Call Discussing Fourth Quarter And Year End 2011 Financial Results And Pipeline Update - PR Newswire 02.16.12 | 08:02 am
- Idenix Pharmaceuticals To Present At Two Upcoming Investor Conferences - PR Newswire 02.07.12 | 04:02 pm
- BioMed Realty Trust To Acquire Cambridge Place For $119 Million - PR Newswire 02.06.12 | 05:02 pm
- Idenix Announces Removal Of The Partial Clinical Hold On HCV Nucleotide Inhibitor, IDX184 - PR Newswire 02.03.12 | 08:02 am
- Idenix Reports Advancement Of HCV Development Pipeline - PR Newswire 01.09.12 | 07:01 am
- Idenix Reports Positive Interim Data For HCV Nucleotide Inhibitor, IDX184 - PR Newswire 01.09.12 | 07:01 am
Partner Headlines for IDIX
- DFC Global Lowers Outlook and 2 Other Stocks At 52-Week Lows - Wall St. Cheat Sheet 04.02.13 | 09:04 am
- Biotech Weekly Recap: Loads Of Bullishness, 2 Giant Rallies, And Selling - Seeking Alpha 12.02.12 | 09:12 am
- RIM, Green Mountain and Other Top Performing Nasdaq Stocks in November - Benzinga 12.01.12 | 01:12 pm
- New Second Generation Combination Therapy For HCV - First Or Best In The Market - Part 3 - Seeking Alpha 11.30.12 | 08:11 am
- UPDATE: Deutsche Bank Initiates Coverage on Idenix Pharmaceuticals with Buy Rating, $7 PT - Benzinga 11.28.12 | 09:11 am
- Morning Market Losers - Benzinga 09.19.12 | 09:09 am
- Idenix's Candidate on Clinical Hold - Analyst Blog - NASDAQ 08.30.12 | 10:08 pm
- Bad News for Bristol-Myers - Analyst Blog - NASDAQ 08.27.12 | 10:08 pm
- Bad News for Bristol-Myers - Analyst Blog - Zacks 08.27.12 | 06:08 pm
- UPDATE: Oppenheimer Maintains Idenix Pharmaceuticals at Perform Following Clinical Hold on IDX19368 - Benzinga 08.27.12 | 01:08 pm
